Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2000

View Archived Issues

Roche and MorphoSys to collaborate on Alzheimer's research

BLA resubmitted for Bexxar

AstraZeneca posts important revisions to Accolate label

Time to ambulation following angioplasty reduced on Neutralase

Photofrin effective in treatment of Barrett's esophagus-related dysplasia

2-5A antisense compound effective against malignant glioma and prostate cancer in mice

Once-daily tramadol enters phase III

Enrollment completed in pivotal phase III trial of Chondrogel

Seattle Genetics initiates phase I trial of SGN-10 combination therapy

Lundbeck and Maxygen establish CNS R&D agreement

Welchol now available in U.S. for treatment of elevated cholesterol

KS Biomedix provides year-end portfolio update

Meningococcal sepsis trial reveals benefits for rBPI21 treatment

SB and Symphar join efforts to discover Lp(a)-lowering agents for atherosclerosis

Nonpeptide Src SH2-binding compounds for osteoporosis designed at Aventis

News from ICAAC: new carbapenem with high activity against MRSA and PRSP

Discovery and profile of highly potent and selective anti-RSV agent presented at ICAAC

New oral HIV entry inhibitor related to AMD-3100 identified by AnorMED

Third-generation NNRTI R-165335/TMC-125 promises to have major impact on HIV therapy

Recordati identifies potent and selective alpha1D-adrenoceptor antagonists based on BMY-7378

Positive efficacy and safety data for daptomycin emerge from phase II trials

Carotene conjugates and their use in tumor diagnosis

Roche prepares new metabotropic glutamate receptor antagonists

Novel conjugated renin inhibitors with prolonged in vivo activity designed at ConjuChem

Bayer's new oxazolidinone antibacterial agents covered by recent patent

Esculentins extracted from plant and found to exert antiinflammatory, antitumor effects

Novel series of PARP inhibitors and their use described by Ono scientists

Indoles under evaluation at AstraZeneca as potential antiinflammatory agents